MEDIROM Healthcare Technologies Inc. (MRM) Cash Flow Statement
Where MRM’s cash came from and went, 2024
December 31, 2024 · Japanese yen- Cash from operations
- −¥1.33B
- Capital expenditures
- ¥564.8M 6.8% of revenue
- Free cash flow
- −¥1.90B −22.9% margin
- Returned to shareholders
- —
- Change in cash
- ¥223.1M cash at year-end ¥329.4M
Drawn to scale: where the cash came from and how it was used. Hover for values.
MRM operating cash flow, capex and free cash flow
MRM cash flow trends, 2018–2024
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | ¥141.9M2018 | −¥1.33B2024 | — | |
| Capital expenditures | ¥34.3M2018 | ¥564.8M2024 | +59.5%/yr | |
| Free cash flow | ¥107.6M2018 | −¥1.90B2024 | — | |
| Free cash flow margin | 3.1%2018 | −22.9%2024 | −26.0 pts | |
| Operating cash flow / net income | 2.142018 | −9.642024 | −11.78 | |
| Stock-based compensation | ¥149,0002018 | ¥02023 | −100.0% | |
| Capex / revenue | 1.0%2018 | 6.8%2024 | +5.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MRM cash flow by activity
MRM net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
MRM cash flow statement in Japanese yen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | ¥138.2M | ¥115.0M | ¥149.0M | −¥990.7M | −¥539.2M | ¥17.3M | ¥66.3M |
| Depreciation & amortization | ¥290.0M | ¥252.6M | ¥184.1M | ¥126.2M | ¥62.3M | ¥46.2M | ¥44.3M |
| Stock-based compensation | — | ¥0 | ¥196.9M | ¥196.9M | ¥139.5M | ¥59.0M | ¥149,000 |
| Change in working capital | ¥2.0M | ¥498.8M | −¥49.9M | ¥1.2M | ¥267.1M | −¥98.5M | −¥120.4M |
| Other non-cash items | −¥1.76B | −¥1.50B | −¥1.17B | ¥109.2M | −¥296.2M | −¥16.2M | ¥151.5M |
| Cash from operating activities | −¥1.33B | −¥631.7M | −¥685.7M | −¥557.2M | −¥366.4M | ¥7.9M | ¥141.9M |
| Investing activities | |||||||
| Capital expenditures | −¥564.8M | −¥135.8M | −¥120.7M | −¥113.8M | −¥73.6M | −¥7.4M | −¥34.3M |
| Investments (net) | ¥361.4M | −¥328.6M | ¥580.4M | −¥72.9M | ¥36.3M | −¥45.4M | −¥79.4M |
| Acquisitions & other investing | ¥564.8M | ¥135.8M | ¥120.7M | ¥102.8M | −¥102.3M | ¥14.9M | ¥34.3M |
| Cash from investing activities | ¥361.4M | −¥328.6M | ¥580.4M | −¥83.9M | −¥139.6M | −¥37.9M | −¥79.4M |
| Financing activities | |||||||
| Net borrowing (repayment) | ¥325.0M | ¥300.9M | ¥340.1M | −¥254.0M | −¥254.0M | −¥241.9M | −¥74.5M |
| Shares issued | ¥868.4M | ¥0 | ¥0 | ¥0 | ¥1.17B | ¥700.0M | ¥0 |
| Other financing | ¥0 | ¥160.3M | ¥0 | −¥174.0M | ¥517.5M | −¥126.1M | ¥0 |
| Cash from financing activities | ¥1.19B | ¥461.2M | ¥340.1M | −¥427.9M | ¥1.43B | ¥332.0M | −¥74.5M |
| Summary | |||||||
| Net change in cash | ¥223.1M | −¥499.1M | ¥234.8M | −¥1.07B | ¥926.1M | ¥301.9M | −¥12.0M |
| Cash at end of period | ¥329.4M | ¥106.3M | ¥605.5M | ¥370.6M | ¥1.44B | ¥513.6M | ¥211.7M |
| Free cash flow | −¥1.90B | −¥767.6M | −¥806.4M | −¥671.0M | −¥440.0M | ¥464,000 | ¥107.6M |
| Free cash flow margin | −22.9% | −11.2% | −11.6% | −12.4% | −13.2% | 0.0% | 3.1% |
| Capex / revenue | 6.8% | 2.0% | 1.7% | 2.1% | 2.2% | 0.2% | 1.0% |
| Operating cash flow / net income | −9.64 | −5.49 | −4.60 | — | — | 0.45 | 2.14 |
| Sep '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Mar '23 | Sep '22 | |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net income | −¥671.1M | ¥720.4M | −¥582.2M | −¥582.2M | ¥470.5M | −¥355.1M | ¥330.5M | −¥90.8M |
| Depreciation & amortization | ¥244.8M | ¥93.9M | ¥196.1M | ¥196.1M | ¥151.7M | ¥100.8M | ¥93.6M | ¥45.2M |
| Stock-based compensation | — | — | — | — | — | — | — | ¥24.0M |
| Change in working capital | ¥217.8M | −¥68.2M | ¥70.1M | ¥70.1M | ¥524.9M | −¥26.1M | −¥243.0M | ¥96.5M |
| Other non-cash items | −¥133.6M | −¥1.29B | −¥515.4M | −¥469.8M | −¥1.12B | −¥329.7M | −¥516.3M | −¥218.1M |
| Cash from operating activities | −¥342.0M | −¥546.0M | −¥831.3M | −¥785.7M | ¥27.8M | −¥610.0M | −¥335.1M | −¥143.2M |
| Investing activities | ||||||||
| Capital expenditures | −¥16.0M | −¥546.1M | −¥18.7M | −¥18.7M | −¥79.6M | −¥56.2M | −¥80.4M | −¥20.2M |
| Acquisitions & other investing | −¥21.1M | ¥144.3M | ¥826.2M | ¥400.3M | −¥416.8M | ¥244.3M | ¥538.6M | ¥105.5M |
| Cash from investing activities | −¥37.1M | −¥401.8M | ¥807.5M | ¥381.6M | −¥496.4M | ¥188.1M | ¥458.2M | ¥85.3M |
| Financing activities | ||||||||
| Shares issued | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Other financing | ¥90.7M | ¥1.13B | ¥64.3M | ¥60.8M | ¥496.6M | −¥57.1M | ¥380.5M | −¥67.1M |
| Cash from financing activities | ¥90.7M | ¥1.13B | ¥64.3M | ¥60.8M | ¥496.6M | −¥57.1M | ¥380.5M | −¥67.1M |
| Summary | ||||||||
| Net change in cash | −¥269.7M | ¥184.8M | ¥23.3M | ¥144.6M | −¥8.4M | −¥545.4M | ¥500.3M | −¥336.5M |
| Cash at end of period | ¥32.6M | ¥329.4M | ¥144.6M | ¥144.6M | ¥105.5M | ¥117.7M | ¥596.7M | ¥100.7M |
| Free cash flow | −¥358.0M | −¥1.09B | −¥804.4M | −¥804.4M | −¥101.3M | −¥666.3M | −¥479.7M | −¥163.4M |
| Free cash flow margin | −11.4% | −22.6% | −23.1% | −23.1% | −2.8% | −20.5% | −12.6% | −10.4% |
| Capex / revenue | 0.5% | 11.3% | 0.5% | 0.5% | 2.2% | 1.7% | 2.1% | 1.3% |
| Operating cash flow / net income | — | −0.76 | — | — | 0.06 | — | −1.01 | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Japanese yen as reported; data from EODHD.
MRM cash generation
In fiscal 2024 (ended December 31, 2024), MEDIROM Healthcare Technologies generated -¥1.3 billion of cash from operations and spent ¥564.8 million on capital expenditures, leaving free cash flow of -¥1.9 billion, −22.9% of revenue. Cash and equivalents rose by ¥223.1 million over the year.
Related: MRM income statement. See the MRM stock overview for the latest quote and news.
MRM cash flow FAQ
What is MEDIROM Healthcare Technologies's free cash flow?
MEDIROM Healthcare Technologies's free cash flow was -¥1.9 billion in fiscal 2024: -¥1.3 billion of operating cash flow minus ¥564.8 million of capital expenditures It was -¥767.6 million a year earlier..
How much cash does MEDIROM Healthcare Technologies generate from operations?
MEDIROM Healthcare Technologies generated -¥1.3 billion of cash from operating activities in fiscal 2024, −9.64 times its net income of ¥138.2 million.
How much does MEDIROM Healthcare Technologies spend on capital expenditures?
MEDIROM Healthcare Technologies spent ¥564.8 million on capital expenditures in fiscal 2024, 6.8% of revenue, compared with ¥135.8 million the year before.